Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201960 | 0.88 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL201961 | 0.88 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL30497375 | 0.88 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL29517073 | 0.88 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL9199180 | 0.82 | CYSLTR2 (0.51) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL9199185 | 0.82 | CYSLTR2 (0.51) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL14843775 | 0.82 | CYSLTR1 (0.47) | CYSLTR2CYSLTR1 | |
| SCHEMBL14843923 | 0.82 | CYSLTR2 (0.46) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL4424897 | 0.82 | CYSLTR2 (0.47) | CYSLTR2CYSLTR1 | |
| SCHEMBL4424900 | 0.82 | CYSLTR2 (0.47) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319007-A1 | DEUTERIUM-ENRICHED MONTELUKAST | PROTIA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319007-A1 | DEUTERIUM-ENRICHED MONTELUKAST | NR3C2, MC2R, CYSLTR1 | CYSLTR2 5/4885CYSLTR1 3/4885PTGER1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.